Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:1024 (30 April), doi:10.1136/bmj.330.7498.1024-a
| The first 150 words of the full text of this article appear below. |
EDITORThe fall in breast cancer deaths in women aged 40-54, first diagnosed under age 50 during 1991-2000, but not invited for screening, could be due to the reduction in the use of oral contraceptives and hormone replacement therapy after warnings of increased risk of thrombosis.1
In 1995-6 several large studies confirmed an increased risk of primary thrombosis of four to six times with different combinations of progestogen and oestrogen.2 Use of "third" generation progestogensdesogestrel, gestodene, and norgestimatewhich had double the risk of thrombosis compared with "second" generation progestogens, sharply declined after warnings of increased risks.
Less than 12 months' use of most hormone replacement formulations increased the risk of breast cancer risk; quantified at 45-63% in the million women study, which also found that current use of hormone replacement doubled the risk of breast cancer and increased breast cancer fatalities by at least 22%. In the million women
Ellen C G Grant, physician
Kingston-upon-Thames KT2 7JU ellengrant@onetel.com
Read all Rapid Responses